Candel Therapeutics (CADL)
(Delayed Data from NSDQ)
$6.70 USD
+0.19 (2.92%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $6.72 +0.02 (0.30%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Candel Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 35 | 70 | 83 | 35 | -99,999 |
Receivables | 0 | 0 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 1 | 2 | 2 | 0 | NA |
Total Current Assets | 37 | 72 | 85 | 35 | NA |
Net Property & Equipment | 3 | 4 | 4 | 3 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 0 | 0 | 0 | 0 | NA |
Total Assets | 41 | 78 | 89 | 38 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 0 | 0 | 2 | 1 | NA |
Current Portion Long-Term Debt | 9 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 4 | 5 | 3 | 3 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 0 | 0 | 0 | NA |
Total Current Liabilities | 14 | 6 | 5 | 5 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 1 | 1 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 12 | 21 | 1 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 1 | 2 | 18 | 7 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 49 | NA |
Total Liabilities | 28 | 30 | 25 | 62 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 150 | 147 | 144 | 20 | NA |
Retained Earnings | -137 | -99 | -80 | -44 | NA |
Other Equity | 0 | 0 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 13 | 48 | 64 | -24 | NA |
Total Liabilities & Shareholder's Equity | 41 | 78 | 89 | 38 | NA |
Total Common Equity | 13 | 48 | 64 | -24 | 0 |
Shares Outstanding | 28.90 | 28.80 | 28.60 | NA | NA |
Book Value Per Share | 0.44 | 1.66 | 2.24 | 0.00 | 0.00 |
Fiscal Year End for Candel Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 26 | 35 | 43 | 52 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 1 | 2 | 1 |
Total Current Assets | NA | 27 | 37 | 45 | 53 |
Net Property & Equipment | NA | 3 | 3 | 4 | 4 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 31 | 41 | 50 | 59 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | NA | 10 | 9 | 6 | 4 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 3 | 4 | 3 | 4 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 14 | 14 | 10 | 8 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 10 | 12 | 15 | 17 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 0 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 25 | 28 | 27 | 28 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 151 | 150 | 149 | 148 |
Retained Earnings | NA | -145 | -137 | -126 | -118 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 6 | 13 | 23 | 31 |
Total Liabilities & Shareholder's Equity | NA | 31 | 41 | 50 | 59 |
Total Common Equity | 0 | 6 | 13 | 23 | 31 |
Shares Outstanding | 29.70 | 29.30 | 28.90 | 28.90 | 28.90 |
Book Value Per Share | 0.00 | 0.20 | 0.44 | 0.80 | 1.06 |